Noelle Sunstrom and the Potential Growth for NeuClone

Noelle Sunstrom, CEO and founder of NeuClone, of Redfern, Australia, discusses the company's future US market prospects and its plans to differentiate from other biosimilar developers.
May 24, 2020
Looking through its robust pipeline of biosimilars, it’s no surprise that Redfern, Australia-based company NeuClone is on its way to becoming a significant player in the biosimilar industry. To date, the company has disclosed information on 6 of its products, 2 of which are being tested in phase 1 clinical trials and an additional 14 are in earlier-stage development. Although market launches may still be years away, NeuClone is definitely gearing up to show the world what it's made of. We spoke with Noelle Sunstrom, CEO and founder of NeuClone, to discuss the company’s outlook on coming to the US market and how it plans to distinguish itself from the competition.

To learn more about NeuCone, visit


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.